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Immunotherapy with T cells expressing chimeric antigen 
receptors (CARs) is an attractive approach to improve 
outcomes for patients with glioblastoma (GBM). IL13Rα2 
is expressed at a high frequency in GBM but not in nor-
mal brain, making it a promising CAR T-cell therapy tar-
get. IL13Rα2-specific CARs generated up to date contain 
mutated forms of IL13 as an antigen-binding domain. 
While these CARs target IL13Rα2, they also recognize 
IL13Rα1, which is broadly expressed. To overcome this 
limitation, we constructed a panel of IL13Rα2-specific 
CARs that contain the IL13Rα2-specific single-chain vari-
able fragment (scFv) 47 as an antigen binding domain, 
short or long spacer regions, a transmembrane domain, 
and endodomains derived from costimulatory molecules 
and CD3.ζ (IL13Rα2-CARs). IL13Rα2-CAR T cells rec-
ognized IL13Rα2-positive target cells in coculture and 
cytotoxicity assays with no cross-reactivity to IL13Rα1. 
However, only IL13Rα2-CAR T cells with a short spacer 
region produced IL2 in an antigen-dependent fash-
ion. In vivo, T cells expressing IL13Rα2-CARs with short 
spacer regions and CD28.ζ, 41BB.ζ, and CD28.OX40.ζ 
endodomains had potent anti-glioma activity confer-
ring a significant survival advantage in comparison to 
mice that received control T cells. Thus, IL13Rα2-CAR 
T cells hold the promise to improve current IL13Rα2-
targeted immunotherapy approaches for GBM and 
other IL13Rα2-positive malignancies.
Received 8 August 2015; accepted 23 October 2015; advance online  
publication 1 December 2015. doi:10.1038/mt.2015.199
INTRODUCTION
The outcome for glioblastoma (GBM) remains poor and immu-
notherapy with vaccines or GBM-specific T cells is one attrac-
tive strategy to improve survival, since it does not rely on the 
cytotoxic mechanisms employed by conventional therapies such 
as chemotherapy and radiation.1–3 Genetic modification with 
chimeric antigen receptors (CARs) allows for the rapid generation 
of tumor-specific T cells. For GBM-targeted CAR T-cell therapies, 
several antigens are actively being pursued including interleukin 
13 receptor α2 (IL13Rα2), human epidermal growth factor recep-
tor 2 (HER2), epidermal growth factor variant III (EGFRvIII), 
and erythropoietin-producing hepatocellular carcinoma A2 
(EphA2).4–11
IL13Rα2, a cancer testis antigen, is an ideal target for CAR 
T-cell therapy for GBM since it is expressed in 50–80% of GBM 
cells and glioma-initiating cells, which are resistant to conven-
tional therapies, but not in normal brain.12–15 IL13Rα2 expres-
sion is associated with poor prognosis,15 and while initial studies 
indicated that IL13Rα2 is a “decoy receptor”, more recent studies 
have demonstrated that IL13Rα2 prevents apoptosis and induces 
TGF-β secretion.16–18
CARs consist of an ectodomain, which is most commonly 
derived from a single-chain variable fragment (scFv), a spacer 
region, a transmembrane domain, and an endomain.19–21 Current 
IL13Rα2-specific CARs do not contain scFvs, but an IL13-mutein 
with one or two amino acid substitutions to preferentially redirect 
T cells to IL13Rα2.7–10 While one study showed that T cells express-
ing IL13-mutein CARs did not recognize IL13Rα1-positive cells,22 
other studies including ours demonstrated that IL13-mutein CAR 
T cells readily recognize IL13Rα1-positive targets raising con-
cerns of ‘on target/off cancer toxicity’.7,8
To selectively target IL13Rα2, we previously had gener-
ated a monoclonal antibody (MAb) and scFv that specifically 
recognized IL13Rα2 (clone 47; scFv47) with a high affinity and 
no cross-reactivity to IL13Rα1.23,24 Here, we report the develop-
ment of IL13Rα2-specific CARs with a scFv47-based antigen-
binding domain (IL13Rα2-CARs). We show that IL13Rα2-CARs 
require a short spacer region for optimal functionality, and that 
IL13Rα2-CAR T cells are able to recognize and kill only IL13Rα2-
positive and not IL13Rα1-positive target cells in vitro. In addition, 
IL13Rα2-CAR T cells induce tumor regression in an orthotopic 
xenograft mouse model of GBM, which was associated with a sig-
nificant survival advantage.
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RESULTS
Generation of IL13Rα2-CAR T cells
We initially generated two retroviral vectors encoding CARs 
based on the IL13Rα2-specific MAb clone 47 (Figure 1a).23,24 
Both CARs contained a N-terminal leader sequence, a codon-
optimized synthetic gene encoding scFv47, a spacer region, a 
CD28 transmembrane domain, and signaling domains derived 
from CD28 and CD3.ζ (Figure 1a). As the spacer region, we 
either used the IgG1 hinge (16 amino acids; short spacer region; 
IL13Rα2-CAR.SSR.CD28.ζ) or the IgG1-CH2CH3 domain (239 
amino acids; long spacer region; IL13Rα2-CAR.LSR.CD28.ζ). As 
controls, LSR and SSR IL13Rα2-CARs without signaling domains 
were constructed (IL13Rα2-CAR.SSR.Δ, IL13Rα2-CAR.LSR.Δ; 
Figure 1a). CD3/CD28-activated T cells from healthy donors 
were transduced with RD114-pseudotyped retroviral particles, 
and 4  to 5 days post-transduction T-cell phenotype and CAR 
expression was determined by fluorescence activated cell sorting 
(FACS) analysis. CARs were expressed on the cell surface with the 
transduction efficiency ranged from 74.1 to 93.3% and no signifi-
cant differences between constructs (Figure 1b,c). Expression of 
full-length IL13Rα2-CAR.SSR.CD28.ζ and IL13Rα2-CAR.LSR.
CD28.ζ was confirmed by western blot using a CD3.ζ antibody 
for detection (Figure 1d). Western blot analysis under nonreduc-
ing conditions revealed no significant differences in dimer/mul-
timer formation between LSR AND SSR CARs (Supplementary 
Figure S2). Phenotypic analysis revealed a mixture CD4- and 
CD8-positive T cells. While the ratio of CD8- to CD4-positive 
T cells was ~3:1 for IL13Rα2-CAR.SSR.CD28.ζ, IL13Rα2-CAR.
SSR.Δ, and IL13Rα2-CAR.LSR.Δ T-cell lines, it was ~1.5:1 for 
IL13Rα2-CAR.LSR.CD28.ζ (Supplementary Figure S1).
IL13Rα2-CAR T cells recognize IL13Rα2 but not 
IL13Rα1
To initially determine the specificity of IL13Rα2-CARs, we cultured 
T cells expressing IL13Rα2-CAR.SSR.CD28.ζ, IL13Rα2-CAR.
LSR.CD28.ζ, IL13Rα2-CAR.SSR.Δ, or IL13Rα2-CAR.LSR.Δ on 
tissue culture plates that were uncoated or coated with recombi-
nant proteins IL13Rα1, IL13Rα2, or IL4Rα. Nontransduced (NT) 
T cells and T cells expressing an IL13mutein-CAR.LSR.CD28.ζ10 
that recognizes IL13Rα1 and IL13Rα2 served as controls. T cells 
expressing IL13Rα2-CAR.SSR.CD28.ζ or IL13Rα2-CAR.LSR.
CD28.ζ produced significant levels of IFNγ (n = 4, P < 0.001) 
when stimulated with recombinant IL13Rα2 proteins in compari-
son to IL13Rα1- or IL4Rα-stimulated T cells (Figure 2a). In con-
trast, T cells expressing IL13Rα2-CAR.SSR.Δ or IL13Rα2-CAR.
LSR.Δ produced no IFNγ in response to all three proteins, indicat-
ing that IFNγ production depends on an intact IL13Rα2-CAR sig-
naling domain. IL13Rα2-CAR.LSR.CD28.ζ T cells also produced 
low levels of IFNγ without activation, indicating “baseline” T-cell 
activation, which was confirmed by intracellular staining for 
Figure 1 Generation of IL13Rα2 CAR T cells. (a) Scheme of IL13Rα2 CARs. All CARs contained an N-terminal leader sequence, a codon-optimized 
synthetic gene encoding for scFv47, a spacer region, a CD28 transmembrane domain, and signaling domains derived from CD28 and CD3.ζ. Spacer 
region was either the IgG1 hinge (16 amino acids; short spacer region; IL13Rα2-CAR.SSR.CD28.ζ) or the IgG1-CH2CH3 domain (239 amino acids; 
long spacer region; IL13Rα2-CAR.LSR.CD28.ζ). LSR.Δ and SSR.Δ IL13Rα2-CARs without signaling domains were constructed and served as controls. 
(b,c) CAR expression was confirmed using FACS analysis. Representative plots (b) and summary data (c) is shown (mean 74.1–93.3%, n = 5–6 per 
CAR construct). (d) Expression of full-length IL13Rα2-CAR.SSR.CD28.ζ and IL13Rα2-CAR.LSR.CD28.ζ by western blot analysis using a CD3-ζ anti-
body. CAR, chimeric antigen receptor.
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phosphorylated CD3.ζ (Supplementary Figure S3). IL13mutein-
CAR.LSR.CD28.ζ T cells produced significant levels of IFNγ in 
the presence of IL13Rα1 (n = 4, P < 0.001) and IL13Rα2 (n = 4, 
P < 0.05) in comparison to NT T cells.
We next confirmed the specificity of IL13Rα2-CAR T cells 
using cell lines that were negative for IL13Rα1 and IL13Rα2 
(Raji), positive for IL13Rα1 (293T-GFP cells), or posi-
tive for IL13Rα1 and IL13Rα2 (U373, 293T-GFP/IL13Rα2; 
Supplementary Figure S4). T cells expressing IL13Rα2-CAR.
SSR.CD28.ζ, IL13Rα2-CAR.LSR.CD28.ζ, IL13Rα2-CAR.
SSR.Δ, or IL13Rα2-CAR.LSR.Δ were cocultured with Raji, 
293T-GFP, or 293T-GFP/IL13Rα2 cells. NT T cells served as 
controls. After 24 hours, media was collected and the concen-
tration of IFNγ and IL2 was determined by ELISA. IL13Rα2-
CAR.SSR.CD28.ζ and IL13Rα2-CAR.LSR.CD28.ζ T cells 
produced significant amounts of IFNγ only in the presence of 
U373 or 293T-GFP/IL13Rα2 cells (Figure 2b) with SSR.CAR 
T cells producing significant more IFNγ than LSR.CAR T cells 
(n = 6, P  < 0.001). IL13Rα2-CAR.SSR.CD28.ζ T cells produced 
also significant amounts of IL2 in the presence of 293T-GFP/
IL13Rα2 and U373 cells, while IL13Rα2-CAR.LSR.CD28.ζ 
T cells did not (Figure 2c). NT T cells and T cells expressing 
IL13Rα2-CAR.SSR.Δ or IL13Rα2-CAR.LSR.Δ produced no 
IFNγ or IL2 in response to any target cells. Finally, we con-
firmed the specificity of IL13Rα2-CAR T cells in standard 
cytotoxicity assays using Raji, 293T-GFP, 293T-GFP/IL13Rα2, 
U373 (Figure 2d). In addition, IL13Rα2-CAR T cells killed 
the IL13Rα2-positive glioma cell line U87 and primary glioma 
cells, while IL13Rα2-negative primary glioma cells were not 
killed (Supplementary Figure S5).
Figure 2 IL13Rα2-CAR T cells release cytokines after stimulation with recombinant IL13Rα2 protein or IL13Rα2-positive cells. IL13Rα2-CAR 
or nontransduced (NT) T cells were stimulated with recombinant IL13Rα1, IL13Rα2, or IL4Rα proteins. After 24 hours, IFNγ (a) was measured by 
ELISA (n = 4). T cells expressing IL13Rα2-CAR constructs, but not controls, expressed significant levels of IFNγ (P < 0.001) when stimulated with 
recombinant IL13Rα2 protein in comparison to IL13Rα1 and IL4Rα stimulated T cells. IL13Rα2-CAR T cells were cocultured with Raji, U373 cells, 
293T-GFP, and 293T-GFP/IL13Rα2 at a 2:1 E:T ratio. NT and CAR.Δ T cells served as controls. (b,c) After 24h cytokines (IFNγ, IL2) were measured by 
ELISA. (b) U373 and 293T-GFP-IL13Rα2 (IFNγ); SSR.Δ versus SSR.CD28.ζ: n = 6, P < 0.001; LSR.Δ versus LSR.CD28.ζ: n = 6, P < 0.05. (c) U373 and 
293T-GFP-IL13Rα2 (IL2); SSR.Δ versus SSR.CD28.ζ: n = 4, P < 0.01; LSR.Δ versus LSR.CD28.ζ: n = 4, NS. (d) Four hours cytotoxicity assay at an E:T 
ratio of 10:1 (n = 4). CAR, chimeric antigen receptor.
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Generation of SSR IL13Rα2-CARs with CD28.OX40.ζ, 
CD28.41BB.ζ, or 41BB.ζ endodomains
While the results described above demonstrated that IL13Rα2-
CAR T cells only recognize IL13Rα2 as judged by cytokine pro-
duction and cytolytic activity, they also highlighted differences 
between LSR and SSR IL13Rα2-CARs. Since only IL13Rα2-CAR.
SSRs produced IL2 in the presence of IL13Rα2-positive target 
cells, we focused in the next set of experiments on IL13Rα2-CARs 
with SSRs, and generated additional CARs with CD28.OX40.ζ, 
CD28.41BB.ζ, or 41BB.ζ endodomains (Figure 3a). CAR T cells 
were generated by retroviral transduction and CAR expression on 
the cell surface was determined by FACS analysis (Figure 3b,c) 
and western blot (Figure 3d). While all CARs were expressed by 
T cells as judged by western blot analysis, IL13Rα2-CAR.SSR.
CD28.41BB.ζ was not expressed on the cell surface, and was 
excluded from further analysis.
Functional comparison of IL13Rα2-CAR.SSR.CD28.ζ, 
IL13Rα2-CAR.SSR.41BB.ζ, and IL13Rα2-CAR.SSR.
CD28.OX40.ζ T cells
To compare the ability of IL13Rα2-CAR.SSR T cells to produce 
IFNγ and IL2 in response to antigen exposure, we performed 
coculture assay with U373 cells. NT and T cells expressing 
IL13Rα2-CAR.SSR.Δ served as controls. All IL13Rα2-CAR.SSRs 
with functional endodomains induced IFNγ and IL2 production 
in the presence of U373 cells, however IL13Rα2-CAR.SSR.41BB.ζ 
T cells produced significantly less (n = 5, P < 0.05) IFNγ in com-
parison to IL13Rα2-CAR.SSR.CD28.ζ and IL13Rα2-CAR.SSR.
CD28.OX40.ζ T cells (Figure 4a). IL13Rα2-CAR.SSR.CD28.ζ 
T cells produced the highest amount of IL2, followed by IL13Rα2-
CAR.SSR.41BB.ζ and IL13Rα2-CAR.SSR.CD28.OX40.ζ T cells. 
In cytotoxicity assays, no significant difference was observed 
between all three constructs using Raji, 293T-GFP, 293T-GFP/
IL13Rα2, and U373 as targets (Figure 4b).
Since all three IL13Rα2-CAR.SSRs T cells with functional 
endodomains produced IL2, we tested all three constructs in our 
orthotopic U373 glioma xenograft mouse model in which T cells 
are directly injected into tumors.6 The model allows for serial 
bioluminescence imaging since U373 are genetically modified to 
express an eGFP.ffLuc fusion protein (U373.eGFP.ffLuc). On day 
0, U373.eGFP.ffLuc cells were injected stereotactically into brains 
of SCID mice, and on day 7 T cells expressing IL13Rα2-CAR.SSR.
CD28.ζ, IL13Rα2-CAR.SSR.41BB.ζ, IL13Rα2-CAR.SSR.CD28.
OX40.ζ, or IL13Rα2-CAR.SSR.Δ were injected intratumorally. 
While mice treated with IL13Rα2-CAR.SSR.Δ T cells showed 
continuous tumor growth within 4 days of T-cell injection, 
mice treated with IL13Rα2-CAR.SSR T cells that had functional 
endodomains did not (Figure 5a,b). Comparison of biolumines-
cence imaging results revealed no significant difference between 
IL13Rα2-CAR.SSR.Δ T cells and the IL13Rα2-CAR.SSR T cells 
groups on the day of T-cell injection. However, mice treated with 
IL13Rα2-CAR.SSR.CD28.ζ or IL13Rα2-CAR.SSR.CD28.OX40.ζ 
T cells had significantly lower tumor signals as early as 1  day 
post-treatment in comparison to mice treated with IL13Rα2-
CAR.SSR.Δ T cells (day 8, P = 0.012 and P = 0.023; Table 1). This 
resulted in a significant survival advantage of IL13Rα2-CAR.SSR.
CD28.ζ or IL13Rα2-CAR.SSR.CD28.OX40.ζ T-cell-treated mice 
(P = 0.0002 and P = 0.0092; Figure 5c). While IL13Rα2-CAR.
Figure 3 Generation of SSR IL13Rα2-CARs with CD28.OX40.ζ, CD28.41BB.ζ or 41BB.ζ endodomains. (a) Scheme of SSR IL13Rα2-CARs. (b,c) 
CAR expression was confirmed using FACS analysis. Representative plots (b) and summary data (c) is shown. IL13Rα2-CAR.SSR.CD28.OX40.ζ and 
IL13Rα2-CAR.SSR.CD28.41BB.ζ: mean: 74.6–77.5% (n = 4); IL13Rα2-CAR.SSR.CD28.41BB.ζ: mean: 4.9% (n = 3). (d) Expression of IL13Rα2-CAR.
SSR.41BB.ζ, IL13Rα2-CAR.SSR.OX40.CD28.ζ, and IL13Rα2-CAR.SSR.41BB.CD28.ζ by western blot analysis. CAR, chimeric antigen receptor.
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SSR.41BB.ζ T-cell-treated mice responded slower resulting in 
a significant difference between IL13Rα2-CAR.SSR.Δ T-cell-
treated on day 14 (P = 0.005; Table 1), treatment also resulted in a 
significant survival advantage (P = 0.0039; Figure 5c). IL13Rα2-
CAR.SSR.CD28.ζ T-cell-treated mice had the longest median 
survival (84 days). However, there was no statistical difference in 
comparison to the median survival of IL13Rα2-CAR.SSR.41BB.ζ 
(63 days) or IL13Rα2-CAR.SSR.CD28.OX40.ζ (56 days) T- 
cell-treated mice.
While IL13Rα2-CAR T cells had potent anti-glioma activity, 
mice eventually developed recurrent gliomas. To investigate the 
etiology of tumor recurrence, U373 cells were isolated from two 
tumor-bearing mice that had been treated either with IL13Rα2-
CAR.SSR.CD28.ζ or IL13Rα2-CAR.SSR.CD28.OX40.ζ T cells. 
FACS analysis after short-term culture revealed cell surface expres-
sion of IL13Rα2, and these cells were readily killed by IL13Rα2-
CAR T cells in cytotoxicity assay (Figure 6). We next determined 
T-cell persistence by bioluminescent imaging of genetically modi-
fied T cells expressing IL13Rα2-CAR.SSR.CD28.ζ and eGFP.ffLuc 
(Luc/IL13Rα2-CAR T cells) injected into U373 tumors. T  cells 
were detected for about 6 days making limited persistence the 
most likely explanation for tumor recurrence (Figure 7).
DISCUSSION
Here, we describe the development and characterization of a new 
scFv-based CAR, IL13Rα2-CAR that is specific for IL13Rα2. 
We show that T cells expressing this CAR can effectively tar-
get and kill IL13Rα2, but not IL13Rα1-positive target cells and 
that only IL13Rα2-CARs with a SSR induce IL2 production in a 
strictly IL13Rα2-dependent manner. Finally, we demonstrate that 
IL13Rα2-CAR.SSR T cells have potent antitumor activity in vivo.
IL13Rα2, a cancer testis antigen, is aberrantly expressed in 
GBM and other malignancies such as melanoma, adrenocorti-
cal carcinoma, colorectal, pancreatic, ovarian cancers.15,25–27 It is 
a promising immunotherapy target since it is not expressed in 
most normal tissues and in one study, using nanostring digital 
RNA counting, belonged to the top 10% of 73 evaluated tumor 
associated antigens that were differentially expressed between 
tumors and normal tissues.25 While IL13Rα2 has been tar-
geted with immunotoxins, vaccines, and antigen-specific T cells 
with encouraging results,10,28,29 few approaches so far have used 
IL13Rα2-specific mAbs or scFvs as targeting moieties for thera-
peutics.24,30 We constructed IL13Rα2-specific, scFv-based CARs 
and determined the influence of long and short spacer regions, 
as well as endodomains on their function. While IL13Rα2-CAR.
SSR.CD28.ζ and IL13Rα2-CAR.LSR.CD28.ζ recognized target 
cells as judged by IFNγ production, only IL13Rα2-CAR.SSR.
CD28.ζ induced IL2 production, indicating better T-cell acti-
vation. We confirmed the inability to induce IL2 expression for 
one additional LSR IL13Rα2-CAR containing a CD28.41BB.ζ 
endodomain (Supplementary Figure S6). Other groups have 
also reported that the length of the spacer region contributes to 
CAR function.31,32 For example, scFvs that bind to an epitope in 
close proximity to the cancer cell membrane, require long spacer 
regions for optimal CAR function in contrast to scFvs that bind 
to epitopes distal to the cell membrane. While the precise epitope 
within the IL13Rα2 molecule for scFv47 is not defined,23,24 it binds 
to the same epitope as the parental MAb 47 that competes with 
IL13 for its binding site.24 Our finding that a SSR confers optimal 
CAR activity suggests that the epitope is located distal to the cell 
membrane.
We constructed four SSR IL13Rα2-CARs with different 
endodomains, CD28.ζ, 41BB.ζ CD28.OX40.ζ, and CD28.41BB.ζ. 
While all four CARs were expressed as judged by western blot 
analysis, however no significant cell surface expression was 
observed for IL13Rα2-CAR.SSR.CD28.41BB.ζ. We explored if 
changing the transmembrane domain from CD28 to CD8α in 
IL13Rα2-CAR.SSR.CD28.41BB.ζ would result in better cell sur-
face expression, however no increased expression was observed 
(Supplementary Figure S7). Since IL13Rα2-CARs.LSR.
Figure 4 Comparison of IL13Rα2-CAR.SSR.CD28.ζ, IL13Rα2-CAR.SSR.41BB.ζ, and IL13Rα2-CAR.SSR.CD28.OX40.ζ T cells. (a) IL13Rα2-CAR 
T cells were cocultured with U373 cells at a 2:1 E:T ratio. NT and CAR.Δ T cells served as controls. After 24 hours, IFNγ and IL2 was measured by 
ELISA (n = 5); SSR.Δ versus SSR.CD28.ζ (U373; IFNγ): P < 0.001; SSR.Δ versus SSR.41BB.ζ (U373; IFNγ): P < 0.05; SSR.Δ versus SSR.CD28.OX40.ζ for 
(U373; IFNγ): P < 0.001; SSR.Δ versus SSR.CD28.ζ (U373; IL2): P < 0.001; SSR.Δ versus SSR.41BB.ζ (U373; IL2): P < 0.001; SSR.Δ versus SSR.CD28.
OX40.ζ (U373; IL2): P < 0.01. (b) Four hours cytotoxicity assay at an E:T ratio of 10:1 (n = 4). CAR, chimeric antigen receptor; ELISA, enzyme-linked 
immunosorbent assay.
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Figure 5 Treatment of glioma xenograft with T cells expressing IL13Rα2-CARs results in tumor regression and improved overall survival. U373 
glioma-bearing mice were treated on day 7 with SSR.CD28.ζ (n = 9), SSR.41BB.ζ (n = 9), or SSR.OX40.CD28.ζ (n = 9) T cells. SSR.Δ CAR T cells (n = 7) 
served as controls. (a) Representative images for each group and (b) quantitative bioluminescence (radiance = photons/sec/cm2/sr) imaging data for 
all mice are shown (dotted lines: individual mice; solid lines: median). (c) Kaplan-Meier survival analysis (SSR.Δ versus SSR.CD28.ζ: P = 0.0002; SSR.Δ 
versus SSR.41BB.ζ: P = 0.0039; SSR.Δ versus SSR.OX40.CD28.ζ: P = 0.0092; SSR.CD28.ζ versus SSR.41BB.ζ: P = 0.4723; SSR.CD28.ζ versus SSR.OX40.
CD28.ζ: P = 0.3582; SSR.41BB.ζ versus SSR.OX40.CD28.ζ: P = 0.8374). CAR, chimeric antigen receptor.
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CD28.41BB.ζ were expressed on the cell surface (Supplementary 
Figure S6), our results suggests that the SSR interferes with effi-
cient CAR trafficking to the cell surface.
Local or systemic injections of conventional as well as CAR 
T cells are actively being explored for high-grade glioma.10,33,34 We 
focused on local injections since in our previous study with human 
EphA2-CAR T cells in SCID mice we only observed antitumor 
activity after local and not after tail vein injection,5 most likely 
reflecting the inability of human T cells to transverse the murine 
blood brain barrier. IL13Rα2-CAR.SSR.CD28.ζ, IL13Rα2-CAR.
SSR.41BB.ζ, and IL13Rα2-CAR.SSR.CD28.OX40.ζ T cells had 
potent antitumor in vivo resulting in a significant survival advan-
tage. While mice treated with IL13Rα2-CAR.SSR.CD28.ζ T cells 
had the longest median survival in comparison to IL13Rα2-CAR.
SSR.41BB.ζ or IL13Rα2-CAR.SSR.CD28.OX40.ζ T-cell-treated 
mice, this difference did not reach significance. Our finding that 
addition of a second costimulatory endodomain does not improve 
antitumor activity in vivo is in agreement with recent findings by 
others.35 While we favor one of our second-generation CARs to 
move forward for further preclinical testing, we are conducting 
additional experiments to establish the minimal effective dose 
of each CAR T-cell population, test their efficacy in additional 
glioma models, and evaluate their ability to kill glioma cells after 
repeated stimulations.
Our data suggest that tumor recurrence is most likely due to 
limited T-cell persistence in the tumor milleu in vivo. This limita-
tion may be overcome by modifying the glioma cells to secrete 
IL-2.22 While effective, this strategy is difficult to translate into 
the clinical setting. We therefore are exploring additional genetic 
modifications of IL13Rα2-CAR T cells to enhance their expan-
sions and persistence like transgenic expression of cytokines36,37 
and/or silencing negative regulators. For example, gliomas express 
PD-L1,38,39 and U373 expresses PD-L1, which is upregulated in the 
presence of IFNγ (Supplementary  Figure S8), and could be tar-
geted in future studies.
While we did not observe immune escape, targeting a single 
antigen is associated with the risk of selecting tumor cells that 
have down regulated the expression or have deleted the targeted 
antigen.40,41 In the context of CAR T cells several groups includ-
ing ours have developed strategies to overcome this limitation by 
infusing two T-cell products with different specificity, expressing 
multiple CARs in T cells or expressing a single CAR with dual 
specificity.42–44
We evaluated IL13Rα2-CAR T cells in a immune-deficient 
mice, which are widely used to study the efficacy of CAR T cells.19 
While ideal to study the interaction between human T cells and 
human tumor cells, immune deficient mice to not recapitulate 
realistically the complex interactions between adoptively trans-
ferred T cells, tumor cells, and the resident immune system, that 
often contributes to the immunosuppressive tumor microenviron-
ment. To overcome this limitation, several groups have developed 
immune-competent mouse models to study CAR T cells.11,45 For 
our IL13Rα2-CAR T cells, such studies would require the genetic 
modification of glioma cells to express human IL13Rα2, since 
scFv47-based CAR T cells do not recognize murine IL13Rα2 
Table 1 Tumor signal comparison
Tumor signal comparison P*
Day 7
  SSR.Δ versus SSR.41BB.ζ 0.917
  SSR.Δ versus SSR.CD28 ζ 0.111
  SSR.Δ versus SSR.CD28.OX40 ζ 0.917
Day 8
  SSR.Δ versus SSR.41BB ζ 0.835
  SSR.Δ versus SSR.CD28 ζ 0.012
  SSR.Δ versus SSR.CD28.OX40 ζ 0.023
Day 14
  SSR.Δ versus SSR.41BB ζ 0.005
  SSR.Δ versus SSR.CD28 ζ 0.015
  SSR.Δ versus SSR.CD28.OX40 ζ 0.015
Day 21
  SSR.Δ versus SSR.41BB ζ 0.010
  SSR.Δ versus SSR.CD28 ζ 0.010
  SSR.Δ versus SSR.CD28.OX40 ζ 0.012
Day 28
  SSR.Δ versus SSR.41BB ζ 0.051
  SSR.Δ versus SSR.CD28 ζ 0.008
  SSR.Δ versus SSR.CD28.OX40 ζ 0.034
*Wilcoxon rank-sum test.
Figure 6 Analysis of U373 cells isolated from recurrent tumors. U373 cells were isolated from recurrent tumor of mice that were treated 
with IL13Rα2-CAR T cells. After short-term culture (2–7 days), FACS analysis and cytotoxicity assays were performed. (a) FACS analysis for IL13Rα2. 
(b) IL13Rα2-CAR T cells killed U373 tumor cells isolated from recurrent tumors in contrast to Raji cells in a standard 4-hour cytotoxicity assay. CAR, 
chimeric antigen receptor.
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(Krenciute et al., unpublished data), or the generation of a murine 
IL13Rα2-specific scFv.
In conclusion, T cells redirected to IL13Rα2 with scFv47-
based CARs have potent antitumor activity against glioma cells 
in vitro, and induce the regression of established GBM xenografts 
in vivo. Our study adds to the growing literature31,32 that there is 
an intricate interplay between scFvs, spacer region, transmem-
brane domain, and endodomain that determines CAR function, 
and that there is no single optimal configuration that is “one size 
fits all”. IL13Rα2-CAR T cells may be of value in the treatment of 
not only IL13Rα2-positive GBMs but also other malignancies in 
which IL13Rα2 is expressed.
MATERIALS AND METHODS
Cell lines. U373 (GBM), U87 (GBM), 293T (human embryonic kidney), 
and Raji (Burkitt’s lymphoma) cell line were purchased from the American 
Type Culture Collection (ATCC; Manassas, VA). GBM4687 and GBMR031 
are primary pediatric GBM cell lines,46 and GBM6 and GBM39 are primary 
adult GBM cell lines.47 The generation of U373 cells expressing enhanced 
green fluorescent protein and firefly luciferase (U373.eGFP.ffLuc), 293T 
cells expressing green fluorescent protein (293T.GFP) or IL13Rα2 and GFP 
(293T.IL13Rα2.GFP) was previously reported.5,7 Cell lines were grown in 
Roswell Park Memorial Institute or Dulbecco's Modified Eagle Medium 
(GE Healthcare Life Sciences HyClone Laboratories, Logan, UT) with 
10% fetal bovine serum (FBS; GE Healthcare Life Sciences HyClone) and 
2 mmol/l GlutaMAX-I (Invitrogen, Carlsbad, CA). The “Characterized 
Cell Line Core Facility” at MD Anderson Cancer Center, Houston, Texas, 
performed cell line validation.
Generation of retroviral vectors encoding IL13Rα2-scFv-specific CARs. 
A  codon-optimized gene was synthesized by GeneArt (Invitrogen) 
containing the immunoglobulin heavy-chain leader peptide, and scFv47 
flanked by 5’ NcoI and 3’ BamHI sites. This mini gene was subcloned 
into SFG retroviral vector containing IL13Rα2-specific CARs (IL13Rα2-
CARs) with short or long spacer regions (SSRs, LSRs) and CD28.ζ, CD28.
OX40.ζ, CD28.41BB.ζ, or 41BB.ζ endodomains.4,48,49 All CARs contained 
a CD28 transmenbrane domain except for IL13Rα2-CAR.SSR.41BB.ζ, 
which had a CD8α transmembrane domain. IL13Rα2-CAR.SSR.Δ and 
IL13Rα2-CAR.LSR.Δ without an endodomain were generated by PCR 
cloning. All cloning of the CARs were verified by sequencing (Seqwright, 
Houston, TX). RD114-pseudotyped retroviral particles were generated by 
transient transfection of 293T cells as previously described.5
Generation of CAR T cells. Human peripheral blood mononuclear cells 
from healthy donors were obtained under a Baylor College of Medicine 
Institutional Review Board-approved protocol, after informed consent 
was obtained in accordance to the Declaration of Helsinki. To generate 
IL13Rα2-CAR T cells, peripheral blood mononuclear cells were isolated 
by Lymphoprep (Greiner Bio-One, Monroe, NC) gradient centrifugation 
and then stimulated on treated nontissue culture 24-well plates, which 
were precoated with OKT3 (CRL-8001, ATCC) and CD28 (BD Bioscience, 
Mountain View, CA) antibodies. Recombinant human interleukin-7 and 
-15 (IL7, 10 ng/ml; IL15, 5 ng/ml; Proleukin; Chiron, Emeryville, CA) 
was added to cultures on day 2.50 On day 3, OKT3/CD28-stimulated T 
cells (2.5 × 105 cells/well) were transduced on RetroNectin (Clontech, 
Mountainview, CA) coated plates in the presence of IL7 and IL15. On day 
5 or 6, T cells were transferred into new wells and subsequently expanded 
with IL-7 and IL15. Nontransduced (NT) T cells were activated with 
OKT3/CD28 and expanded in parallel with IL-7 and IL-15. IL13Rα2-CAR 
expression was determined 4 to 5 days post-transduction.
Flow cytometry. A FACSCalibur (BD Bioscience) or BC Gallios 
(Beckman Coulter, Brea, CA) instruments were used to acquire immu-
nofluorescence data which were analyzed with CellQuest (BD Bioscience) 
Figure 7 Limited persistence of IL13Rα2-CAR T cells in vivo. SSR.CD28.ζ-CAR T cells were transduced to express eGFP.ffLuc. (a) FACS analysis con-
firmed the expression of CAR and eGFP.ffLuc transgenes. (b,c) 1 × 105 unmodified U373 cells were injected intracranially into mice. On day 7, mice 
received 2 × 106 SSR.CD28.ζ.eGFP.ffLuc CAR T cells intracranially using the same tumor coordinates. Bioluminescence imaging was used to monitor 
T-cell persistence. CAR, chimeric antigen receptor.
100 101 102
Q1
2.04%
Q2
7.74%
Q4
24.3%
Q3
65.9%
Q1
28.3%
Q2
48.2%
Q4
8.96%
Q3
14.6%
103 104
100
GFP
101
102
103
104a
b c
Luc T cells
IL
13
Rα
2-
CA
R
100
101
102
103
104
100 101 102 103 104
Luc/IL13Rα2-CAR T cells
Luc T cells
d1
d2
d4
d6
Luc/IL13Rα2-CAR T cells 5.0 × 107
4.0 × 107
3.0 × 107
2.0 × 107R
ad
ia
nc
e
1.0 × 107
0
0 1 2 3
Days post T-cell injection
U373+Luc T cells
U373+Luc/IL13Rα2-CAR T cells
4 5 6
Molecular Therapy vol. 24 no. 2 feb. 2016 361
© The American Society of Gene & Cell Therapy
IL13Rα2-specific T Cells for Glioblastoma
or BC Gallios (Beckman Coulter) respectively. FlowJo v.7 (FlowJo, LLC 
Ashland, OR) or Kaluza v1.2 (Beckman Coulter) were used for final data 
analysis and graphic representation. Isotype controls were immunoglobu-
lin G1–fluorescein isothiocyanate (IgG1-FITC; BD Bioscience), IgG1–
phycoerythrin (IgG1-PE; BD Bioscience). SSR IL13Rα2-CAR expression 
was detected by staining T cells with human IL13Rα2 chimera (R&D 
Systems, Minneapolis, MN) followed by Fc-FITC (Milipore, Billerica, 
MA) or Fc-PE (SouthernBiotech, Birmingham, AL). LSR IL13Rα2-CARs 
were detected using Fc-FITC or Fc-PE. U373 cells were analyzed for 
PD-L1 expression using a CD271 PE antibody (BD Bioscience). Forward 
and side scatter gating were used to discriminate live cells from dead cells. 
Cells were collected and washed once with PBS (Sigma, St. Louis, MO) 
containing 1% FBS (GE Healthcare Life Sciences HyClone Laboratories; 
FACS buffer) prior to the addition of antibodies. Cell were incubated for 
30 minutes on ice in the dark, washed once, and fixed in FACS buffer with 
0.5% paraformaldehyde (BD Bioscience) prior to analysis.
Western blot. Cells were dissociated with PBS + 3 mmol/l ethylenedi-
aminetetraacetic acid and lysed in a buffer containing 50 mmol/l Tris, 
150 mmol/l NaCl, 5 mmol/l Ethylenediaminetetraacetic acid, 1% Triton 
X-100 (all from Sigma), and protease inhibitors (Thermo Scientific, 
Waltham, MA). Protein concentrations were determined using a Bio-
Rad protein assay (Bio-Rad, Hercules, CA) with bovine serum albumin 
as the standard. Samples were denatured in Laemmli buffer (Bio-Rad) 
with βME (2-mercaptoethanol, Bio-Rad; reducing conditions) or with-
out βME (nonreducing condition) at 95 °C for 5 minutes. Cell lysate 
(5 μg per lane) were run on a 10% SDS polyacrylamide gel and trans-
ferred to nitrocellulose membranes (BioRad). Membranes were blocked 
with 5% milk powder in Tris-buffered saline + 0.1% Tween-20 (all 
from Sigma) and then probed with anti-CD3.ζ (sc-1239, Santa Cruz 
Biotechnology, Santa Cruz, CA) or glyceraldehyde-3-phosphate dehy-
drogenase (sc-47724, Santa Cruz Biotechnology) mouse monoclonal 
antibodies followed by a horseradish peroxidase-conjugated goat mouse 
IgG antibody (sc-2005, Santa Cruz Biotechnology). Blots were developed 
using SuperSignal West Dura Extended Duration Substrate (Thermo 
Scientific) and exposed to GeneMate Blue Basic Autoradiography Film 
(BioExpress, Kaysville, UT).
Coculture assays for coculture assays, each CAR was expressed in T cells 
from the same donor. Biological repeats were done using different donors 
and data presented in the figures is the average of three to five donors.
Recombinant protein coculture assay. Nontissue culture 24-well plates 
were precoated with recombinant human IL13Rα1, IL13Rα2, or IL4Rα 
proteins, (R&D Systems) at a final concentration of 500 ng/well. Plates 
were washed once using Roswell Park Memorial Institute, and CAR or NT 
T cells were plated. After 24 hours, supernatants were harvested and IFNγ 
and IL2 release was measured by ELISA per the manufacturer’s instruc-
tions (R&D Systems).
Cell culture coculture assay. CAR T cells were cocultured with target 
cells at a 2:1 effector to target (E:T) ratio in a 24-well plate. NT T cells 
served as controls. After 24 hours, culture supernatants were harvested, 
and the presence of IFNγ and IL2 was determined by ELISA as per the 
manufacturer’s instructions (R&D Systems).
Cytotoxicity assay. Standard chromium (51Cr) release assays were per-
formed as previously described.5 Briefly, 1 × 106 target cells were labeled 
with 0.1 mCi (3.7MBq) 51Cr and mixed with decreasing numbers of effec-
tor cells to give effector to target ratios of 40:1, 20:1, 10:1, and 5:1. Target 
cells incubated in complete medium alone or in 1% Triton X-100 were 
used to determine spontaneous and maximum 51Cr release, respectively. 
After 4 hours, supernatants were collected and radioactivity was measured 
in a gamma counter (Cobra Quantum; PerkinElmer; Wellesley; MA). The 
mean percentage of specific lysis of triplicate wells was calculated accord-
ing to the following formula: (test release–spontaneous release)/(maximal 
release–spontaneous release) × 100.
Orthotopic xenograft SCID mouse model. All animal experiments fol-
lowed a protocol approved by the Baylor College of Medicine Institutional 
Animal Care and Use Committee. Experiments were performed as 
described previously5 with a few modifications. ICR-SCID mice were pur-
chased from Taconic (IcrTac:ICR-Prkdcscid; Fox Chase C.B-17 SCID ICR; 
Taconic, Hudson, NY). Male 7- to 9-week-old mice were anesthetized, the 
head was shaved and the mice were immobilized in a Cunningham Mouse/
Neonatal Rat Adaptor (Stoelting, Wood Dale, IL) stereotactic apparatus fit-
ted into an E15600 Lab Standard Stereotaxic Instrument (Stoelting), and 
then scrubbed with 1% povidone-iodine. A 10-mm skin incision was made 
along the midline. The tip of a 30G ½ inch needle mounted on a Hamilton 
syringe (Hamilton, Reno, NV) served as the reference point. A 1 mm burr-
hole was drilled into the skull 1 mm anterior and 2 mm to the right of the 
bregma. 1 × 105 U373.eGFP.ffLuc cells in 2.0 µl were injected 3-mm deep 
to the bregma, corresponding to the center of the right caudate nucleus 
over 5 minutes. The needle was left in place for 3 minutes, to avoid tumor 
cell extrusion, and then withdrawn over 5 minutes. Seven days after tumor 
cell injection, animals were treated with 2 × 106 effector cells in 2 µl to the 
same tumor coordinates. The incision was closed with 2–3 interrupted 7.0 
Ethilon sutures (Ethicon, Somerville, NJ). A subcutaneous injection of 
0.03–0.1 mg/kg buprenorphine (Buprenex RBH, Hull, England) was given 
for pain control.
Bioluminescence imaging. Isofluorane anesthetized animals were imaged 
using the IVIS system (IVIS, Xenogen, Alameda, CA) 10–15 minutes after 
150 mg/kg D-luciferin (Xenogen) was injected per mouse intraperitone-
ally. The photons emitted from the luciferase-expressing tumor cells were 
quantified using Living Image software (Caliper Life Sciences, Hopkinton, 
MA). A pseudo-color image representing light intensity (blue least intense 
and red most intense) was generated and superimposed over the grayscale 
reference image. Mice were euthanized when the tumor radiance was 
greater than 1 × 109 on two occasions or when they met euthanasia criteria 
(neurological deficits, weight loss, signs of distress) in accordance with the 
Center for Comparative Medicine at Baylor College of Medicine.
Statistical analysis. All in vitro experiments were performed at least in 
triplicate, GraphPad Prism 5 software (GraphPad software, La Jolla, CA) 
was used for statistical analysis. Measurement data were presented as 
mean ± standard deviation. The differences between means were tested by 
appropriate tests. The significance level used was P < 0.05. For the mouse 
experiments, changes in tumor radiance from baseline at each time point 
were calculated and compared between groups using t-test or Wilcoxon 
rank-sum test, whichever appropriate. Survival determined from the time 
of tumor cell injection was analyzed by the Kaplan-Meier method and dif-
ferences in survival between groups were compared by the Wilcoxon test.
SUPPLEMENTARY MATERIAL
Figure S1. Phenotypic analysis of IL13Rα2-CAR T-cell lines.
Figure S2. Western blot of IL13Rα2-CAR T cells.
Figure S3. IL13Rα2-CAR.LSR.CD28.ζ induces constitutive CD3.ζ 
phosphorylation.
Figure S4. Cell surface expression of IL13Rα1 and IL13Rα2.
Figure S5. Cell surface expression of IL13Rα2 in brain tumor cell lines.
Figure S6. Generation and characterization of LSR.CD28.41BB.ζ 
CAR T cells.
Figure S7. Generation of SSR.CD28.41BB.ζ CAR T cells.
Figure S8. FACS analysis of PD-L1 expression on U373 cell surface 
with and without IFNγ stimulation.
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